Swedish Orphan Biovitrum launches Willfact under its distribution agreement with LFB BIOMEDICAMENTS.

(From Hugin)

Stockholm, Sweden, Les Ulis, France - April 8 , 2010 - Swedish Orphan Biovitrum (STO: BVT) and LFB BIOMEDICAMENTS today announced the launch of Willfact in Germany, a new product for treatment of the bleeding disorder von Willebrand disease. Swedish Orphan Biovitrum and LFB also announced the prolongation of the current distribution agreement through 2014.

Swedish Orphan Biovitrum will, under the agreement with LFB BIOMEDICAMENTS, distribute Willfact in Germany, Sweden, Norway, Iceland, Denmark, Estonia, Latvia, Lithuania, Czech Republic, Slovakia, Hungary and Bulgaria. A Mutual Recognition Procedure is planned in the forthcoming months to secure marketing authorization in the majority of the other countries where Swedish Orphan Biovitrum has the right to distribute Willfact.

"The opportunity of making Willfact available to patients with von Willebrand disease in Germany and elsewhere will be a valuable contribution to improving the life of these patients. We look forward to a fruitful and continued …